Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Li Fangyu, in the future development of the company through the acquisition of additional shares, indicating a positive outlook for the company's growth [1] Share Acquisition by Director - Li Fangyu has increased her stake in the company by acquiring 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - The shares were purchased through LIFY Management Holdings Limited in the open market, reflecting her strong belief in the company's prospects [1] Share Buyback Program - The company has repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Management's Perspective - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as a demonstration of management's confidence in the long-term value of the company, which is expected to enhance the capital market value and shareholder return capabilities [1] - The buyback aligns with the overall interests of the company and its shareholders [1]
美丽田园医疗健康(02373)获非执行董事李方雨增持4.15万股